AbCellera Biologics (ABCL) to Release Earnings on Thursday

AbCellera Biologics (NASDAQ:ABCL - Get Free Report) is anticipated to issue its quarterly earnings data after the market closes on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.15) per share and revenue of $7.58 million for the quarter. Parties that wish to register for the company's conference call can do so using this link.

AbCellera Biologics Stock Performance

Shares of ABCL stock traded down $0.10 on Friday, hitting $3.05. The company had a trading volume of 1,700,109 shares, compared to its average volume of 3,961,455. The firm has a market cap of $899.40 million, a P/E ratio of -4.98 and a beta of 0.42. The stock's 50-day moving average is $3.09 and its two-hundred day moving average is $2.83. AbCellera Biologics has a twelve month low of $2.34 and a twelve month high of $5.26.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. KeyCorp dropped their target price on AbCellera Biologics from $5.00 to $4.00 and set an "overweight" rating on the stock in a report on Wednesday, January 8th. Benchmark restated a "hold" rating on shares of AbCellera Biologics in a report on Tuesday, November 5th. Finally, Stifel Nicolaus restated a "buy" rating and issued a $12.00 target price (down previously from $14.00) on shares of AbCellera Biologics in a report on Tuesday, November 5th.

AbCellera Biologics Company Profile

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.